• Streptozotocin Models: From β-Cell Loss to Neuropathy

  2026-08-17

  Streptozotocin and STZ are more than tools for experimental diabetes mellitus induction: they are experimental perturbations that connect β-cell injury with downstream neuroinflammation. This guide shows how to design interpretable diabetes research assays and apply mechanistic lessons from TBK1-driven painful diabetic neuropathy.

• Gamithromycin Pharmacodynamics Against MmmSC

  2026-08-17

  The reference study advances evaluation of contagious bovine pleuropneumonia therapeutics by integrating MIC testing, time-kill kinetics, matrix comparison, and post-antibiotic-effect analysis for gamithromycin. Its findings show strong matrix-dependent susceptibility but predominantly mycoplasmastatic activity, providing a more informative basis for designing subsequent clinical studies than susceptibility testing alone.

• Everolimus (RAD001): From mTOR Mechanism to Impact

  2026-08-16

  A translational framework for using Everolimus (RAD001) to connect mTOR biology, assay design, and cancer research decisions without confusing growth inhibition with cell death.

• Everolimus (RAD001): Measure the Right Response

  2026-08-15

  Everolimus (RAD001) can suppress proliferation without directly proving cell death. This evidence-based guide applies Schwartz’s relative-versus-fractional viability framework to mTOR experiments, helping researchers interpret cancer cell proliferation inhibition, apoptosis assay results, and translational potency more accurately.

• Capecitabine in Patient-Derived Tumor Assembloids

  2026-08-14

  Capecitabine is a fluoropyrimidine prodrug whose apparent activity depends on enzymatic activation and tumor context. This article explains how patient-derived gastric cancer assembloids can improve interpretation of drug response, stromal resistance, and apoptosis-oriented assays in preclinical oncology research.

• PDHA1 Succinylation and Macrophage Immune Escape

  2026-08-14

  A 2025 Nature Communications study identifies PDHA1 K83 succinylation as a metabolic–immune link in cholangiocarcinoma. The work shows that altered PDH activity increases tumor-microenvironment α-KG, suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling, and may create a rationale for combining CPI-613 with gemcitabine and cisplatin.

• Epacadostat: An IDO1 Assay-to-Immunity Framework

  2026-08-13

  Epacadostat (INCB024360) is examined through an assay-to-immunity framework that connects IDO1 biochemical potency with cellular and whole-blood immune readouts. Learn how to interpret matrix effects, cytokine changes, and checkpoint-inhibitor combination studies without overstating translational evidence.

• Losmapimod in p38 MAPK Research Workflows

  2026-08-13

  Losmapimod (GW856553X) enables coordinated studies of p38α/β inhibition, inflammatory signaling, and vascular biology rather than relying on a single endpoint. This workflow-centered guide shows how to pair kinase inhibition with phosphatase and pathway readouts while avoiding common solubility, timing, and interpretation errors.

• Bestatin Hydrochloride: An Assay Design Guide

  2026-08-12

  Bestatin hydrochloride (Ubenimex) is more than a broad aminopeptidase inhibitor: it can function as a pathway-dissection tool. This guide connects classic angiotensin neurophysiology with angiogenesis inhibition, tumor growth and invasion research, and practical assay design.

• DPI: A Strategic Probe for Redox-cAMP Biology

  2026-08-12

  Diphenyleneiodonium chloride is more than a conventional NADH oxidase inhibitor: its redox-enzyme activity and GPR3-linked cAMP effects create both a powerful experimental opportunity and a major interpretation challenge. This thought-leadership guide connects DPI-enabled pathway dissection with recent evidence that iron, reactive oxygen species, and ferroptosis-like defense can shape plant–pathogen resistance.

• CPI-613 and Tumor–Immune Metabolic Reprogramming

  2026-08-11

  CPI-613 links mitochondrial enzyme inhibition with tumor–immune metabolic research. This article interprets new cholangiocarcinoma findings and translates them into practical assay, control, and combination-treatment decisions.

• RapaLink-1: A Precision mTOR Resistance Tool

  2026-08-11

  RapaLink-1 is a third-generation mTOR inhibitor engineered to address resistance at both allosteric and kinase-domain binding sites. This article presents an assay-centered framework for interpreting mTORC1 inhibition, glioma phenotypes, and reversible dormancy without confusing reduced proliferation with irreversible cell death.

• Suhuang, ER Stress, and NLRP3 in Cough Variant Asthma

  2026-08-10

  The reference study links endoplasmic reticulum stress to NLRP3 inflammasome activation and pulmonary dysfunction in an ovalbumin-induced model of cough variant asthma. Its main contribution is a mechanistic pathway connecting calcium trafficking, PKCε, TXNIP, and the RIP1-RIP3-Drp1 axis, while showing that Suhuang antitussive capsule protects pulmonary homeostasis through ER-stress suppression.

• CP-673451 PDGFRα/β Assay Workflows

  2026-08-09

  CP-673451 is a selective PDGFRα/β inhibitor for separating PDGF-driven signaling from broader receptor tyrosine kinase effects. This guide translates its biochemical potency into reproducible phosphorylation, angiogenesis, ATRX-stratified glioma, and xenograft research workflows.

• Radicicol Hsp90 Inhibitor Workflows

  2026-08-08

  Radicicol is a mechanistic Hsp90 inhibitor for dissecting antigen cross-presentation, adipocyte differentiation, apoptosis, and inflammatory signaling. This practical guide connects target-selective assay design with formulation, dosing, controls, and troubleshooting across cellular and in vivo models.

8420 records 2/562 page Previous Next 12345 下5页 Last page